These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 22535619)

  • 1. Increased suppressor of cytokine signaling-3 expression predicts mucosal relapse in ulcerative colitis.
    Li Y; Nuij VJ; Baars JE; Biermann K; Kuipers EJ; Peppelenbosch MP; de Haar C; Janneke van der Woude C
    Inflamm Bowel Dis; 2013 Jan; 19(1):132-40. PubMed ID: 22535619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission.
    Xu AT; Li Y; Zhao D; Shen J; Xu XT; Qiao YQ; Zhu MM; Wang TR; Cui Y; Ai LY; Ran ZH
    Inflamm Bowel Dis; 2015 Feb; 21(2):241-50. PubMed ID: 25545374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
    Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
    Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT1, STAT6 and adenosine 3',5'-cyclic monophosphate (cAMP) signaling drive SOCS3 expression in inactive ulcerative colitis.
    Li Y; Deuring J; Peppelenbosch MP; Kuipers EJ; de Haar C; van der Woude CJ
    Mol Med; 2012 Dec; 18(1):1412-9. PubMed ID: 23154639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of mucosal suppressors of cytokine signaling 3 expression in ulcerative colitis.
    Miyanaka Y; Ueno Y; Tanaka S; Yoshioka K; Hatakeyama T; Shimamoto M; Sumii M; Chayama K
    World J Gastroenterol; 2007 Jun; 13(21):2939-44. PubMed ID: 17589943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fecal calprotectin measurement is a marker of short-term clinical outcome and presence of mucosal healing in patients with inflammatory bowel disease.
    Kostas A; Siakavellas SI; Kosmidis C; Takou A; Nikou J; Maropoulos G; Vlachogiannakos J; Papatheodoridis GV; Papaconstantinou I; Bamias G
    World J Gastroenterol; 2017 Nov; 23(41):7387-7396. PubMed ID: 29151692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis.
    Hassan EA; Ramadan HK; Ismael AA; Mohamed KF; El-Attar MM; Alhelali I
    Saudi J Gastroenterol; 2017; 23(4):238-245. PubMed ID: 28721978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of mucosal tumor necrosis factor-α: A new criterion for discontinuing infliximab therapy in ulcerative colitis.
    Olsen T; Rismo R; Gundersen MD; Paulssen EJ; Johnsen K; Kvamme JM; Goll R; Florholmen J
    Cytokine; 2016 Mar; 79():90-5. PubMed ID: 26775117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count.
    Nakarai A; Kato J; Hiraoka S; Inokuchi T; Takei D; Moritou Y; Akita M; Takahashi S; Hori K; Harada K; Okada H; Yamamoto K
    World J Gastroenterol; 2014 Dec; 20(48):18367-74. PubMed ID: 25561804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histological healing after infliximab induction therapy in children with ulcerative colitis.
    Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
    World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
    Bryant RV; Burger DC; Delo J; Walsh AJ; Thomas S; von Herbay A; Buchel OC; White L; Brain O; Keshav S; Warren BF; Travis SP
    Gut; 2016 Mar; 65(3):408-14. PubMed ID: 25986946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute histological inflammatory activity is associated with clinical relapse in patients with ulcerative colitis in clinical and endoscopic remission.
    Calafat M; Lobatón T; Hernández-Gallego A; Mañosa M; Torres P; Cañete F; Cabré E; Ojanguren I; Domènech E
    Dig Liver Dis; 2017 Dec; 49(12):1327-1331. PubMed ID: 28958412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histological Markers of Clinical Relapse in Endoscopically Quiescent Ulcerative Colitis.
    Kevans D; Kirsch R; Dargavel C; Kabakchiev B; Riddell R; Silverberg MS
    Inflamm Bowel Dis; 2020 Oct; 26(11):1722-1729. PubMed ID: 31883337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
    Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
    World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoscopic mucosal healing and histologic remission in ulcerative colitis: a systematic literature review of clinical, quality-of-life and economic outcomes.
    Pandey A; Achrafie L; Kodjamanova P; Tencer T; Kumar J
    Curr Med Res Opin; 2022 Sep; 38(9):1531-1541. PubMed ID: 35608153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of Fecal Markers with Magnifying Endoscopic Stratification in Patients with Ulcerative Colitis Who Are in Clinical Remission.
    Mine S; Takeshima F; Akazawa Y; Matsushima K; Minami H; Yamaguchi N; Ohnita K; Isomoto H; Nakao K
    Digestion; 2018; 97(1):82-89. PubMed ID: 29393146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fecal Calprotectin Levels Predict Histological Healing in Ulcerative Colitis.
    Patel A; Panchal H; Dubinsky MC
    Inflamm Bowel Dis; 2017 Sep; 23(9):1600-1604. PubMed ID: 28590341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission.
    Wakai M; Hayashi R; Tanaka S; Naito T; Kumada J; Nomura M; Takigawa H; Oka S; Ueno Y; Ito M; Chayama K
    BMC Gastroenterol; 2020 Apr; 20(1):85. PubMed ID: 32245401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon.
    Rigby RJ; Simmons JG; Greenhalgh CJ; Alexander WS; Lund PK
    Oncogene; 2007 Jul; 26(33):4833-41. PubMed ID: 17297444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical implications of histologic abnormalities in colonic biopsy specimens from patients with ulcerative colitis in clinical remission.
    Feagins LA; Melton SD; Iqbal R; Dunbar KB; Spechler SJ
    Inflamm Bowel Dis; 2013 Jun; 19(7):1477-82. PubMed ID: 23702713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.